Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001344867 | SCV001538950 | likely benign | Qualitative or quantitative defects of dysferlin | 2024-07-02 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV003145594 | SCV003831257 | uncertain significance | not provided | 2020-12-16 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004036438 | SCV004861676 | uncertain significance | Inborn genetic diseases | 2023-11-20 | criteria provided, single submitter | clinical testing | The c.3392C>A (p.S1131Y) alteration is located in exon 31 (coding exon 31) of the DYSF gene. This alteration results from a C to A substitution at nucleotide position 3392, causing the serine (S) at amino acid position 1131 to be replaced by a tyrosine (Y). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001831109 | SCV002082276 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2B | 2020-03-10 | no assertion criteria provided | clinical testing |